AU2008206486C1 - Tetrahydrobiopterin prodrugs - Google Patents

Tetrahydrobiopterin prodrugs Download PDF

Info

Publication number
AU2008206486C1
AU2008206486C1 AU2008206486A AU2008206486A AU2008206486C1 AU 2008206486 C1 AU2008206486 C1 AU 2008206486C1 AU 2008206486 A AU2008206486 A AU 2008206486A AU 2008206486 A AU2008206486 A AU 2008206486A AU 2008206486 C1 AU2008206486 C1 AU 2008206486C1
Authority
AU
Australia
Prior art keywords
cycloalkyl
heterocycloalkyl
alkenyl
alkenylenec
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008206486A
Other languages
English (en)
Other versions
AU2008206486A1 (en
AU2008206486B2 (en
Inventor
Sianna Castillo
Erik Foehr
Emil D. Kakkis
Paul John Kostel
Steven W. Szczepanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of AU2008206486A1 publication Critical patent/AU2008206486A1/en
Application granted granted Critical
Publication of AU2008206486B2 publication Critical patent/AU2008206486B2/en
Publication of AU2008206486C1 publication Critical patent/AU2008206486C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008206486A 2007-01-12 2008-01-09 Tetrahydrobiopterin prodrugs Ceased AU2008206486C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88472707P 2007-01-12 2007-01-12
US60/884,727 2007-01-12
PCT/US2008/050637 WO2008089008A2 (en) 2007-01-12 2008-01-09 Tetrahydrobiopterin prodrugs

Publications (3)

Publication Number Publication Date
AU2008206486A1 AU2008206486A1 (en) 2008-07-24
AU2008206486B2 AU2008206486B2 (en) 2013-04-18
AU2008206486C1 true AU2008206486C1 (en) 2013-09-26

Family

ID=39535519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008206486A Ceased AU2008206486C1 (en) 2007-01-12 2008-01-09 Tetrahydrobiopterin prodrugs

Country Status (10)

Country Link
US (2) US20100016328A1 (cg-RX-API-DMAC7.html)
EP (1) EP2114944A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010515747A (cg-RX-API-DMAC7.html)
AR (1) AR064874A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008206486C1 (cg-RX-API-DMAC7.html)
CA (1) CA2675134A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000094A1 (cg-RX-API-DMAC7.html)
PE (1) PE20081612A1 (cg-RX-API-DMAC7.html)
TW (1) TW200843778A (cg-RX-API-DMAC7.html)
WO (1) WO2008089008A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821970A2 (pt) 2008-01-03 2015-06-23 Biomarin Pharm Inc Análogos de pterina para tratamento de condição responsiva a bh4
JP2011508781A (ja) 2008-01-07 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド テトラヒドロビオプテリンの合成方法
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
TW201241005A (en) 2011-02-18 2012-10-16 Alexion Pharma Inc Methods for synthesizing molybdopterin precursor Z derivatives
ES2773376T3 (es) * 2011-08-31 2020-07-10 Catabasis Pharmaceuticals Inc Amidas de ácidos grasos, composiciones y procedimientos de uso
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
EP2773212B1 (en) 2011-10-31 2024-08-07 The Johns Hopkins University Methods and compositions for treatment of autism
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175359A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
EP2852571A4 (en) 2012-05-23 2015-11-25 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
JP2015529218A (ja) 2012-09-08 2015-10-05 セリックスビオ プライヴェート リミテッド 炎症と脂質障害の治療のための組成物及び方法
WO2014041446A2 (en) * 2012-09-17 2014-03-20 Mahesh Kandula Compositions and methods for the treatment of metabolic diseases
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
US20190076434A1 (en) * 2016-04-01 2019-03-14 University Of Utah Research Foundation Methods of treating peripheral vascular diseases, including systemic sclerosis vasculopathy
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
US11471963B2 (en) 2019-01-25 2022-10-18 Black & Decker Inc. Reciprocating saw blade

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079574A1 (en) * 1981-11-13 1983-05-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing biopterin and its derivatives
CH651755A5 (en) * 1982-03-03 1985-10-15 Kanegafuchi Chemical Ind Use of pterin derivatives
EP0209669A1 (en) * 1985-05-24 1987-01-28 Salvador Herrero, Manuel-Ramon A device for checking condensers and coils of motor vehicles
EP0722731B1 (en) * 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601215A (en) * 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US3505329A (en) * 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS574990A (en) * 1980-05-09 1982-01-11 Bisukonchiini Matsukusu Polyacylated tetrahydropterin derivative and manufacture
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS59112987A (ja) * 1982-12-20 1984-06-29 Kanegafuchi Chem Ind Co Ltd １′，２′―ジアシル―（６ｒ，ｓ）―５，６，７，８―テトラヒドロ―ｌ―ビオプテリンおよびその製法
US5196533A (en) * 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) * 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) * 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) * 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
CA1262347A (en) * 1985-01-28 1989-10-17 Suntory Limited Preparation process of (6r)-tetrahydro-l-biopterin
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
JPS61293983A (ja) * 1985-06-22 1986-12-24 Kanegafuchi Chem Ind Co Ltd ５ｎ−アシルテトラヒドロプテリン化合物
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
DE3853711T2 (de) * 1987-11-30 1996-01-11 Vitamin Kenkyusho Kk Zwischenverbindungen für die Synthese von 5,6,7,8-Tetrahydro-L-erythro-biopterin und seiner Derivate.
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4308739C1 (de) * 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
WO1998004558A1 (en) * 1996-07-31 1998-02-05 Artemis, Inc. Active oxygen scavengers containing pterin derivatives
JP4306825B2 (ja) * 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
WO2005049000A2 (en) * 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Treatment of phenylketonurias with bh4
EP1776364A2 (en) * 2003-11-17 2007-04-25 BioMarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
US20060194800A1 (en) * 2005-01-07 2006-08-31 University Of Strathclyde Pteridine derivatives as nitric oxide synthase activators
BRPI0821970A2 (pt) * 2008-01-03 2015-06-23 Biomarin Pharm Inc Análogos de pterina para tratamento de condição responsiva a bh4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079574A1 (en) * 1981-11-13 1983-05-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing biopterin and its derivatives
CH651755A5 (en) * 1982-03-03 1985-10-15 Kanegafuchi Chemical Ind Use of pterin derivatives
EP0209669A1 (en) * 1985-05-24 1987-01-28 Salvador Herrero, Manuel-Ramon A device for checking condensers and coils of motor vehicles
EP0722731B1 (en) * 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Also Published As

Publication number Publication date
AU2008206486A1 (en) 2008-07-24
TW200843778A (en) 2008-11-16
WO2008089008A3 (en) 2008-10-09
CL2008000094A1 (es) 2008-05-23
CA2675134A1 (en) 2008-07-24
JP2010515747A (ja) 2010-05-13
PE20081612A1 (es) 2008-11-12
EP2114944A2 (en) 2009-11-11
US20100016328A1 (en) 2010-01-21
WO2008089008A2 (en) 2008-07-24
AR064874A1 (es) 2009-04-29
AU2008206486B2 (en) 2013-04-18
US20120022072A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
AU2008206486C1 (en) Tetrahydrobiopterin prodrugs
AU2008347005B2 (en) Pterin analog for treating BH4 responsive condition
US11926640B2 (en) Prodrugs of glutamine analogs
US20160096848A1 (en) Selective inhibitors for protein kinases and pharmaceutical composition and use thereof
US20100009997A1 (en) Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
US20220048906A1 (en) Compounds and uses thereof
EP3773544B1 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
US20240325370A1 (en) Therapeutic regimens of a degrader of brd9
AU2015398613A1 (en) Pharmaceutical combinations of organo-arsenoxide compounds and mTOR inhibitors
WO2016079067A1 (en) Compounds targeting the bfl-1 anti-apoptotic protein and uses thereof for the treatment of cancer
WO2018204987A1 (en) Carbonic anhydrase inhibitors
US20250346572A1 (en) Non-acid inhibitors of inositol hexakisphosphate kinase (ip6k) and methods of use thereof
JP2006298892A (ja) 抗癌剤
HK1256284B (en) Prodrugs of glutamine analogs

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAY 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAY 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired